Thromb Haemost 1994; 71(06): 773-777
DOI: 10.1055/s-0038-1642521
Review Article
Schattauer GmbH Stuttgart

Factor VII Mie: Homozygous Asymptomatic Type I Deficiency Caused by an Amino Acid Substitution of His (CAC) for Arg(247) (CGC) in the Catalytic Domain

Michiaki Ohiwa
1   The Department of Molecular Biology on Genetic Disease, Mie University School of Medicine, Tsu-city, Mie, Japan
2   The Second Department of Internal Medicine, Mie University School of Medicine, Tsu-city, Mie, Japan
,
Tatsuya Hayashi
1   The Department of Molecular Biology on Genetic Disease, Mie University School of Medicine, Tsu-city, Mie, Japan
,
Hideo Wada
2   The Second Department of Internal Medicine, Mie University School of Medicine, Tsu-city, Mie, Japan
,
Kouzou Minamikawa
2   The Second Department of Internal Medicine, Mie University School of Medicine, Tsu-city, Mie, Japan
,
Shigeru Shirakawa
2   The Second Department of Internal Medicine, Mie University School of Medicine, Tsu-city, Mie, Japan
,
Koji Suzuki
1   The Department of Molecular Biology on Genetic Disease, Mie University School of Medicine, Tsu-city, Mie, Japan
› Author Affiliations
Further Information

Publication History

Received: 13 December 1993

Accepted after revision: 24 February 1994

Publication Date:
09 July 2018 (online)

Summary

We found hereditary factor VII deficiency in a clinically asymptomatic family, and characterized their factor VII gene and the abnormal molecule using recombinant DNA techniques. The propositus was a 45-year-old woman who was noted to have a prolonged prothrombin time. The level of factor VII antigen of the patient was 25.9% of that of normal individuals and the level of factor VII activity was 28% and 24%, when tested using rabbit brain tissue factor and human placental tissue factor in a one-stage clotting assay, respectively. Two of her sisters had almost the same reduced levels of factor VII antigen and activity, and her parents who are first cousins, a son, a daughter and a niece had moderately reduced leves of both factor VII activity and antigen. To identify the mutation site, all the coding exons and exon-intron boundaries of the factor VII gene of the propositus were amplified using the polymerase chain reaction (PCR), then subcloned and sequenced. One mis- sense mutation (G to A) was identified in exon VIII of the gene resulting in an amino acid substitution of His(CAC) for Arg(247)(CGC) in the gene product. PCR using a mutagenic primer to introduce a new kpaL I site into the mutant allele of the patient’s factor VII gene revealed that this allele was inherited in the affected individuals in the pedigree. Transient expression assays using BHK cells transfected with an expression vector containing the mutant factor VII cDNA suggested that this mutation leads to factor VII deficiency by impairing secretion of the mutated factor VII. This is the first report of a single point mutation which induces factor VII deficiency with both activity and antigen reduced in parallel.

 
  • References

  • 1 Kisiel W, Davie EW. Isolation and characterization of bovine factor VII. Biochemistry 1975; 14: 4928-34
  • 2 Broze Jr GJ, Majerus PW. Purification and properties of human coagulation factor VII. J Biol Chem 1980; 255: 1242-7
  • 3 Radcliffe R, Nemerson Y. Activation and control of factor VII by activated factor X and thrombin. J Biol Chem 1975; 250: 388-95
  • 4 Seligsohn U, Osterud B, Brown SF, Griffin JH, Rapaport SI. Activation of human factor VII in plasma and in purified systems. J Clin Invest 1979; 64: 1056-65
  • 5 Zur M, Radcliffe RD, Oberdick J, Nemerson Y. The dual role of factor VII in blood coagulation. Initiation and inhibition of a proteolytic system by a zymogen. J Biol Chem 1982; 257: 5623-31
  • 6 Radcliffe R, Nemerson Y. Mechanism of activation of bovine factor VII . J Biol Chem 1976; 251: 4797-802
  • 7 Bajaj SP, Rapaport SI, Brown SF. Isolation and characterization of human factor VII. Activation of Factor VII by Factor Xa. J Biol Chem 1980; 256: 253-9
  • 8 Jackson CM, Nemerson Y. Blood coagulation. Ann Rev Biochem 1980; 49: 765-811
  • 9 Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: Additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74: 5260-4
  • 10 Ruf W, Rehemtulla A, Edgington TS. Phospholipid-independent and -dependent interactions required for tissue factor receptor and cofactor function. J Biol Chem 1991; 266: 2158-66
  • 11 Triplett DA, Brandt JT, Batard MAM, Dixon JLS, Fair DS. Hereditary factor VII deficiency: Heterogenity defined by combined functional and immunochemical analysis. Blood 1985; 66: 1284-8
  • 12 James HL, Kumar A, Girolami A, Hubbard JG, Fair DS. Variant coagulation factor X and VII with point mutation in a highly conserved motif in the substrate binding pocket. Thromb Haemost (Abstr) 1991; 65: 937
  • 13 O’Brien DP, Gale KM, Anderson JS, McVey JH, Miller GJ, Meade TW, Tuddenham EGD. Purification and characterization of factor VII 304-Gln: A variant molecule with reduced activity isolated from a clinically unaffected male. Blood 1991; 78: 132-40
  • 14 Chaing SH, High KA, Severe F. VII deficiency associated with two mis-sense mutations in the factor VII gene. Thromb Haemost (Abstr) 1991; 66: 1262
  • 15 Hagen FS, Gray CL, O’Hara PJ, Grant FJ, Saari GC, Woodbury RG, Hart CE, Insley M, Kisiel W, Kurachi K, Davie EW. Characterization of a cDNA coding for human factor VII. Proc Natl Acad Sci USA 1986; 83: 2412-6
  • 16 O’Hara PJ, Grant FJ, Haldeman BA, Gray CL, Insley MY, Hagen FS, Murray MJ. Nucleotide sequence of the gene coding for human factor VII a vitamin K-dependent protein participating in blood coagulation. Proc Natl Acad Sci USA 1987; 84: 5158-62
  • 17 Blin N, Stafford DW. A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acids Res 1976; 3: 2303-8
  • 18 Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erich HA. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988; 239: 487-91
  • 19 Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitorsr. Proc Natl Acad Sci USA 1977; 74: 5463-7
  • 20 Graham FL, von der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 1973; 52: 456-67
  • 21 Matsushita T, Emi N, Yamamoto K, Sugiura I, Takamatsu J, Saito H. Gene analysis of abnormal Factor VII Nagoya (Arg304 → Trp), which was specifically activated by thromboplastin of different species. Jpn J Thromb Hemost 1991; 2: 239 (Abstr in Japanese)
  • 22 Takamiya O, McVey JH, Kemball-Cook G, Tuddenham EGD. Dysfunctional human factor VII variants: Detection of missense mutations by PCR and single-strand conformational polymorphisms (SSCP). Thromb Haemost (Abstr) 1993; 69: 1291
  • 23 Kuppuswarmy MN, Sabharwal AK, Birktoft JJ, Bajaj SP. Molecular charcterization of human factor VII Kansas (GK704): Substitution of Gin100 by Arg in one allele and Arg304 by Gin possibly in the other allele. Thromb Haemost (Abstr) 1993; 69: 1292
  • 24 James HL, Fink LM, Fair DS. Factor VII Little Rock is dysfunctional due to an Arg304 to Gin substitution. Thromb Haemost (Abstr) 1993; 69: 1292
  • 25 Kumar A, Blumenthal DK, Fair DS. Identification of molecular sites on factor VII which mediate its assembly and function in the extrinsic pathway activation complex. J Biol Chem 1991; 66: 915-21